ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
PARIS—Oligoclonal bands, together with symptomatic lesions disseminated in space, increase the risk of multiple sclerosis (MS),...
Conference Coverage
DMTs Reduce the Risk of Conversion to Secondary Progressive MS
PARIS—Secondary progressive multiple sclerosis (MS) is at least partly a consequence of early inflammation, and the risk of...
Conference Coverage
The Diagnostic Value of 2010 McDonald Criteria Versus 2016 MAGNIMS Guidelines for Special MS Populations
PARIS—When faced with patients with clinically isolated syndrome (CIS) or primary progressive multiple sclerosis (PPMS),...
Conference Coverage
Can McArdle’s Sign Help Diagnose MS?
PARIS—McArdle’s sign, a rapidly reversible motor weakness induced by head flexion in patients with suspected multiple sclerosis (...
Conference Coverage
Serum Neurofilament Light Levels May Reflect the Efficacy of MS Treatments
PARIS—It is possible to gauge the effects of disease-modifying therapies (DMTs) for multiple sclerosis (MS) by measuring serum...
Conference Coverage
Can a Saliva Test Provide a New Biomarker for MS?
PARIS—A non-invasive test that assesses immunoglobulin free light chains in saliva may detect immunopathologic changes in the...
Conference Coverage
Smoking, vitamin D deficiency linked to early MS disability
LONDON – Severe vitamin D deficiency and current smoking predicted accumulated disability in patients with clinically isolated syndrome, which can...
Conference Coverage
Fluoxetine fails to slow progressive multiple sclerosis
LONDON – Contrary to expectation of a neuroprotective benefit, fluoxetine does not slow down the progressive phase of multiple sclerosis,...
Conference Coverage
Neuronal protein could be multiple sclerosis blood biomarker
LONDON
Conference Coverage
Mobility benefits of MS drug dalfampridine confirmed by patient-reported outcomes
LONDON – After 6 months on extended-release dalfampridine, patients with relapsing-remitting multiple sclerosis reported that their ability to...
Conference Coverage
Alemtuzumab, natalizumab found equally effective for relapsing-remitting MS
Key clinical point:Alemtuzumab and natalizumab are similarly effective at preventing relapse and disability progression in patients with relapsing...
Conference Coverage
Ocrelizumab Increases Likelihood of No Evidence of Disease Progression
LONDON—Treatment with ocrelizumab increases the proportion of patients with primary progressive multiple sclerosis (MS) with no...
Conference Coverage
Arbaclofen Extended-Release Tablets Are Effective for MS Spasticity
LONDON—Arbaclofen extended-release tablets administered twice per day are an efficacious and safe treatment for spasticity in...
Conference Coverage
Siponimod curbs disability in secondary progressive multiple sclerosis
Key clinical point: Siponimod is an investigational treatment that could help patients with secondary progressive multiple sclerosis. Major...